1-(2-fluoro-5-nitrophenyl)isoquinoline | 1609355-94-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(2-fluoro-5-nitrophenyl)isoquinoline
• 英文别名: 1-(2-Fluoro-5-nitrophenyl)isoquinoline
• CAS: 1609355-94-3
• 化学式: C₁₅H₉FN₂O₂
• 分子量: 268.247
• InChiKey: XWVWXBXIIALJCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2-fluoro-5-nitrophenyl)isoquinoline 在 tin(II) chloride dihdyrate 作用下， 以 乙醇 为溶剂， 以80.6%的产率得到4-fluoro-3-(isoquinolin-1-yl)aniline
  参考文献：
  名称：

  [EN] CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY
  [FR] DÉRIVÉS CONTENANT UN SULFONAMIDE CYCLIQUE EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION HEDGEHOG

  摘要：

  该发明通常涉及含有环磺酰胺衍生物的创造和使用，用于抑制刺猬信号通路，并将这些化合物用于治疗高增殖性疾病和介导血管生成的疾病。

  公开号：

  WO2014071298A1
• 作为产物：
  描述：

  1-氯异喹啉 、 2-氟-5-硝基苯硼酸 在 四(三苯基膦)钯 、 lithium hydroxide 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 4.5h， 以27.5%的产率得到1-(2-fluoro-5-nitrophenyl)isoquinoline
  参考文献：
  名称：

  [EN] CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY
  [FR] DÉRIVÉS CONTENANT UN SULFONAMIDE CYCLIQUE EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION HEDGEHOG

  摘要：

  该发明通常涉及含有环磺酰胺衍生物的创造和使用，用于抑制刺猬信号通路，并将这些化合物用于治疗高增殖性疾病和介导血管生成的疾病。

  公开号：

  WO2014071298A1

文献信息

• CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY
  申请人：NANT HOLDINGS IP, LLC

  公开号：US20150299190A1

  公开（公告）日：2015-10-22

  The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.

  本发明通常涉及使用含环磺酰胺基衍生物的创建和使用以抑制刺猬信号通路，并将这些化合物用于治疗高增殖性疾病和血管生成介导的疾病。
• Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
  申请人：NantBioScience, Inc.

  公开号：US10183013B2

  公开（公告）日：2019-01-22

  The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.

  本发明一般涉及含有环磺酰胺的衍生物的创制和使用，以抑制刺猬信号通路，并将这些化合物用于治疗过度增殖性疾病和血管生成介导的疾病。
• COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF T-CELL EXHAUSTION USING CD39 BIOMARKERS AND MODULATORS
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：EP3207063A2

  公开（公告）日：2017-08-23
• METHODS FOR MODULATING IMMUNE RESPONSES DURING CHRONIC IMMUNE CONDITIONS BY TARGETING IL-27 INDUCED PATHWAYS
  申请人：THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：US20150284459A1

  公开（公告）日：2015-10-08

  Described herein are novel compositions comprising IL-27 or NFIL-3 modulators (i.e., inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating TIM-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases.
• METHODS FOR IN VIVO EXPANSION OF CD8+ T CELLS AND PREVENTION OR TREATMENT OF GVHD
  申请人：CITY OF HOPE

  公开号：US20200095321A1

  公开（公告）日：2020-03-26

  Disclosed herein are methods of preventing and treating acute GVHD and chronic GVHD after hematopoietic cell transplantation (HCT), as well as methods of in vivo augmenting expansion of donor CD8 + T cells in the lymphoid tissues in vivo after HCT and methods of augmenting recipient tissue expression of programmed death-ligand 1 (PD-L1, or B7H1) after HCT. The methods entail administering one or more doses of an effective amount of a therapeutic agent to a recipient simultaneously, immediately before, or immediately after HCT to temporarily deplete CD4 + T cells or to reduce serum IL-2. Some examples include an anti-CD4 antibody or an anti-CD4-meditope-immunotoxin, an anti-IL-2 antibody, an agent blocking IL-2R, and/or a PD-L1-Ig. One or more additional therapeutic agents such as IFN- can be administered.